Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Bavarian leader questions Germany's Eurovision participation - 2King Charles shares cancer treatment update, says it's a 'personal blessing'
- 3Which Brilliant Home Gadget Can't You Reside Without?
- 4Brazil expands pesticide packaging reverse logistics
- 5True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- ‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- Purchases of iPhone 17 Pro soar across Gaza amid 'limited' humanitarian aid
- Japanese H3 rocket fails during launch of navigation satellite (video)
- Study casts doubt on potential for life on Jupiter's moon Europa
- Record-breaking flu hospitalizations in New York in a single week: Health officials
- 25 Most Beautiful Villages in France You Can Actually Visit
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- OECD: Iran war dampening global growth
- The most effective method to Pick the Best Material Organization: Insider Tips
